Lucas Porras

Mr. Lucas Porras

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
LPLucas Porras
Lucas Porras
HIHoussam Ismail
Houssam Ismail
Sylvie MaderSylvie Mader
Sylvie Mader
Estrogen receptor alpha (ERα, NR3A1) contributes through its expression in different tissues to a spectrum of physiological processes, including reproductive system development and physiology, bone mass maintenance, as well as cardiovascular and central nervous system functions. It is also one of the main drivers of tumorigenesis in breast and uterine cancer and can be targeted by several types of hormonal therapies. ERα is expressed in a subset of luminal cells corresponding to less than 10% of normal mammary epithelial cells and in over 70% of breast tumors (ER+ tumors), but the basis for its selective expression in normal or cancer tissues remains incompletely understood. The mapping of alternative promoters and regulatory elements has delineated the complex genomic structure of the ESR1 gene and shed light on the mechanistic basis for the tissue-specific regulation of ESR1 expression. However, much remains to be uncovered to better understand how ESR1 expression is regulated in breast cancer. This review recapitulates the current body of knowledge on the structure of the ESR1 gene and the complex mechanisms controlling its expression in breast tumors. In particular, we discuss the impact of genetic alterations, chromatin modifications, and enhanced expression of other luminal transcription regulators on ESR1 expression in tumor cells.

6 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LPLucas Porras
Lucas Porras
FGFaustine Gorse
Faustine Gorse
NTNdeye Khady Thiombane
Ndeye Khady Thiombane
LGLouis Gaboury
Louis Gaboury
Sylvie MaderSylvie Mader
Sylvie Mader
Estrogen receptor alpha (ERα) expression in ~2/3 breast tumors selects patients for hormonal therapies. Tumors negative for ERα but positive for the progesterone receptor (PR, encoded by PGR) have also been candidates for ER-targeting therapies, as PR expression may reflect undetected ER activity. Conversely, PR− status in ER+ tumors predicts a worse therapeutic response. Our analysis of breast tumor transcriptome datasets, however, revealed that in tumors with lower PGR expression, the clinical PR status does not correlate accurately with the expression of ESR1 or of ER target genes, including PGR itself. We identified carbonic anhydrase 12 (CA12) as an estrogen target gene better correlated with ESR1 than PGR, reflecting CA12 regulation by both ERα and the luminal factor and upstream ESR1 regulator GATA3. Immunostaining supported strong positive correlations at the protein level with ERα and GATA3 in a cohort of 118 tumors. Most ER+PR− tumors expressed CAXII at levels similar to those of ER+PR+ tumors, consistent with observations in tumor transcriptome datasets and with active estrogenic signaling in some ER+PR− breast cancer cell lines. The few ER−PR+ tumors did not express CAXII or the other luminal markers FOXA1 and GATA3. Overall, CAXII is a luminal marker that can help interpret ER status in single ER/PR positive tumors.

28 October 2026 in Cancer Research
Verified
Journal Article
Closed access
LPLucas Porras
Lucas Porras
MCMarina Carrière
Marina Carrière
AGAnn-Sophie Gironne
Ann-Sophie Gironne
HPHugo Philippeau
Hugo Philippeau
GAGabriel Alzial
Gabriel Alzial
GDGeneviève Deblois
Geneviève Deblois
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.